Illustrative only
GeographyUSSortRisk-adj.
Indication comparison
Ten indications compared on six dimensions, sortable by any column: ATTR cardiomyopathy leads on risk-adjusted value at $209m, and Type 2 diabetes trails at $35m despite the largest addressable pool.
- IndicationATTR cardiomyopathyPhase IIIAddressable45,000Unmet need3.0Competition2.5Pricing4.5PoS55%LaunchQ3 ’28Risk-adj.$209m
- IndicationHeart failure (HFrEF)Phase IIIAddressable430,000Unmet need4.0Competition2.0Pricing2.5PoS50%LaunchQ3 ’29Risk-adj.$146m
- IndicationChronic kidney diseasePhase IIAddressable1,900,000Unmet need4.0Competition2.5Pricing2.0PoS20%LaunchQ4 ’32Risk-adj.$104m
- IndicationHeart failure (HFpEF)Phase IIAddressable610,000Unmet need4.5Competition3.0Pricing3.0PoS25%LaunchQ2 ’31Risk-adj.$103m
- IndicationHypertrophic cardiomyopathyPhase IIAddressable90,000Unmet need3.5Competition2.5Pricing4.0PoS32%LaunchQ4 ’31Risk-adj.$77m
- IndicationObesityPhase IAddressable2,800,000Unmet need2.5Competition1.0Pricing2.5PoS12%LaunchQ2 ’33Risk-adj.$77m
- IndicationPulmonary arterial hypertensionPhase IIAddressable25,000Unmet need3.0Competition2.0Pricing4.5PoS35%LaunchQ3 ’31Risk-adj.$53m
- IndicationIgA nephropathyPhase IIAddressable60,000Unmet need3.5Competition2.0Pricing4.0PoS28%LaunchQ2 ’30Risk-adj.$50m
- IndicationMASHPhase IIAddressable800,000Unmet need3.5Competition2.5Pricing2.5PoS15%LaunchQ3 ’32Risk-adj.$45m
- IndicationType 2 diabetesPhase IAddressable3,400,000Unmet need2.0Competition1.0Pricing1.5PoS10%LaunchQ4 ’33Risk-adj.$35m
Risk-adjusted is peak sales × probability of success.